<DOC>
	<DOCNO>NCT02095925</DOCNO>
	<brief_summary>Cancer patient increase risk deep venous thrombosis pulmonary embolism , collectively term venous thromboembolism ( VTE ) . Risk assessment score VTE cancer patient previously develop group Khorana Vienna CATS . However , routine thromboprophylaxis ambulatory cancer patient base score currently recommend . In investigator prospective , observational cohort study , investigator aim identify cancer patient high risk VTE base clinical characteristic , coagulation biomarkers coagulant activity tissue factor bearing microparticles .</brief_summary>
	<brief_title>Cohort Study Identify Cancer Patients High Risk Venous Thromboembolism</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<criteria>Stage III IV esophageal carcinoma , gastric carcinoma , intestinal carcinoma , pancreatic carcinoma , ovarian cancer , breast carcinoma , prostate cancer , urothelial cell carcinoma lung carcinoma ( small cell nonsmall cell ) start chemotherapy 3 month ago Chemotherapy start 3 month ago within 7 day enrollment Aged 18 year old Written inform consent Use anticoagulant ( heparin , vitamin K antagonist direct oral anticoagulant ) Adjuvant chemotherapy ( i.e . surgery curative intent )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>